Part of the problem is that a GIA decision would result in JT diversifying away from Omega-3's. My fear is he would engage in costly acquisitions.
Does the world really need another BP? Most BP sell at fairly low PE multiples because their best selling products have a limited life.
Why not accept the "right" deal if it comes along. Even if JT did a deal for Europe with cash up front what would he do with that cash? My guess is he would pursue acquisitions.
Why not entertain takeout offers when the market is hot for new Cardiovascular drugs? If the stars line up for a solid AMRN takeover why would anyone tempt fate by turning it down?
Amarinbull- I think JT has made it clear, no partnership will be announced in Europe until US labeling and prosecution of EMA application. I think there’s no chance of Europe partner. BB
News 
Market Data 
Discover 
